<DOC>
	<DOCNO>NCT01000233</DOCNO>
	<brief_summary>Intervention study focus prevent progression aortic valve calcification . Vascular cardiac calcification marker risk poor outcome , especially severe calcify aortic stenosis coronary calcification . Its increase prevalence health problem . The knowledge therapeutic objective condition change recent year pathophysiological aspect present , focus atherosclerotic disease inflammation . Several clinical trial fail demonstrate statin ACE inhibitor prevent progression cardiovascular calcification . Taking account new concept ectopic calcification research result group , logical approach prevent progression would early intervention management calcification inhibit agent phytate ( inositol six-phosphate -- InsP6 ) . Hypothesis : The phytate prevents delay progression cardiovascular calcification . It clinical trial intervention oral phytate ( InsP6 ) patient mild moderate cardiovascular calcification ( aortic valve / coronary artery ) compare placebo period 24 month . It prospective , randomized minimization variable ensure homogeneity group . The primary analysis time evolution extent calcium aortic valve coronary artery make CT . Secondary variable degree progression aortic stenosis clinical event ( death , stroke , angina , stroke cancer type ) .</brief_summary>
	<brief_title>Value Oral Phytate ( InsP6 ) Prevention Progression Cardiovascular Calcifications</brief_title>
	<detailed_description>Main objective study : To evaluate whether progression aortic valve calcification and/or coronary artery group treat oral InsP6 small placebo group , measure quantification calcium ( score mass ) multidetector CT inclusion study 24 month . Secondary : To observe whether progression aortic stenosis severity intervention group small placebo group , evaluate echocardiography . To compare clinical event intervention placebo group , measure combined event death , hospitalization angina , coronary revascularization ( surgical percutaneous ) , nonfatal myocardial infarction stroke type . To compare adverse effect collect spontaneous report two group . Main variable analysis ( multidetector CT measurement ) : Calcium aortic valve and/or coronary artery assess Agatston unit ( AU ) two occasion : treatment , 2 year follow . Types analysis main variable : - Percentage change quantity calcium aortic valve baseline study end . - Absolute difference quantity calcium aortic valve baseline study end . - Percentage change coronary calcium quantity baseline study end . - Absolute difference coronary calcium quantity baseline study end . - Percentage change total calcium aortic valve coronary artery baseline study end . - Absolute difference total calcium aortic valve coronary artery baseline study end . Secondary analysis : Progression aortic stenosis severity assess gradient maximum speed , average echocardiography . Percentage clinical event . The event consider composite event `` death , hospitalization angina , coronary revascularization ( surgical percutaneous ) , valvular surgery , nonfatal myocardial infarction stroke type '' Measurements : Calcium valve echocardiography : express Rosenhek score aortic coronary calcium CT MD : express Agatston score unit mass determination calcium . Measurement emit radiation . Demographic variable : age , sex , race , weight , height , BMI SC , snuff alcohol habit . Food Survey : Quality frequency feed relation income Ins6P . Conventional hematological biochemical parameter : blood count . ESR . Urea , Creatinine , Na , K , Ca , P Phytate : determination urine InsP6 technique develop Universitat Illes Balears . The blind maintain final result . Events qualifier : death , nonfatal myocardial infarction , hospitalization angina , coronary revascularization , stroke ( score Events Committee study ) . Adverse event : Determination adverse event accord RD 223/2004 ( Spanish regulation ) Patient Compliance : By count return capsule quantification phytate urine . Withdrawals : If withdrawal reason patient request authorization calcium measurement CT possible . Statistical : Predetermination sample size : Assuming evolution aortic valve calcification 21.7 % 32 % per year find placebo arm clinical trial similar methodology population , base standard deviation 1100 AU per year , assume Type I error 0.05 type II 0.2 , detect difference 20 % annually treatment , need 124 105 patient , respectively , assume 10 % loss , average Agatston unit baseline , 1700 . We decide adopt large size . Strategy statistical analysis : The analysis data carry maintain blind conduct intention treat , secondary analysis , per protocol . The population intention treat analysis , include randomized patient receive least one dose assign treatment . The per protocol population consist individual finish study without protocol violation . A description baseline characteristic group , carry , verify , despite use system random assignment , homogeneity two group baseline variable . A test normality quantitative variable select statistic descriptor , mean ( CI95 % ) median ( RI ) , test comparison . The main result change aortic valve calcification , calculated percentage change baseline divide duration follow year . An analysis stratify independent variable . An increment least 18 % basal calcification , consider evident progression , contrast , less progression consider response treatment . Logistic regression use establish likelihood response . Secondary objective analyze compare ratio treatment group . There descriptive analysis side effect list group . Ethical consideration : No special ethical problem arise trial phytate consider safe product ( FDA-Title 21 subchapter GRSH E-Part 582 ) component normal diet , chance problem excessive intake nil . Nor amend intervene study routine clinical practice . The important aspect control radiation dose patient receive multidetector CT . In case low environmental background radiation receive 6 month . Considering aspect , intermediate CT study schedule . No information available extent calcium multidetector-CT let u build sample size great confidence . We use value progressive study Cowell Houslay make approximation .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Calcium aortic valve , characterize Rosenhek score grade 2 3 echocardiography / severe coronary calcification detect study ( angiography , CT ) . Exclusion criterion : Severe aortic ( Rosenhek 4 ) coronary calcification . Positive pregnancy test ( pregnancy occur study defer final evaluation end gestation , patient wish continue study ) . Addiction drug alcohol . Renal insufficiency ( serum creatinine &gt; 2mg/dl ) . Liver disease cirrhosis . Severe valve disease require surgery study . Unstable ischemic heart disease ( revascularization last 3 month ) . Atrial fibrillation initial evaluation ( difficulty measure Ca ) . May include later sinus rhythm achieve stable least three month . The need medication relation calcium metabolism ( PTH , bisphosphonates , strontium ranelate , raloxifene , oral calcium , vitamin D , calcitonin , etc. ) . Participation another trial three month prior evaluation . Suspected difficulty accomplish two year , reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>PATOLOGIC CALCIFICATION</keyword>
	<keyword>AORTIC VALVE STENOSIS</keyword>
	<keyword>INOSITOL HEXAPHOSPHATE</keyword>
</DOC>